// App-Quantinova.ai

125 : Five-Year Analysis of Murano Study Demonstrates Enduring Undetectable Minimal Residual Disease (uMRD) in a Subset of Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Patients (Pts) Following Fixed-Duration Venetoclax-Rituximab (VenR) Therapy (Tx)

Researchers

Presenter

  • Arnon P. Kater

Principal Investigators

  • Barbara Eichhorst

  • Peter Hillmen

  • James D'Rozario

  • Carolyn Owen

  • Sarit E Assouline

  • Nicole Lamanna

  • Tadeusz J. Robak

  • Javier de la Serna

  • Ulrich Jaeger

  • Guillaume Cartron

  • Marco Montillo

  • Clemens Mellink

  • Brenda J. Chyla

  • Cameron Wilson

  • Jenny Wu

  • Yanwen Jiang

  • Marcus Lefebure

  • Michelle Boyer

  • John F. Seymour

Medical Centers

  • Cancer Center Amsterdam, Amsterdam, Netherlands

  • UC San Diego Moores Cancer Center, San Diego, CA

  • Department I of Internal Medicine and Center of Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf, University of Cologne, Cologne, Germany

  • St. James's University Hospital, Leeds, United Kingdom

  • The John Curtin School of Medical Research, Australian National University, Canberra, Australia

  • Segal Cancer Center, Lady Davis Institute, Jewish General Hospital, Montreal, QC, Canada

  • Columbia University Medical Center and Herbert Irving Comprehensive Cancer Center, New York, NY

  • Medical University of Lodz and Copernicus Memorial Hospital, Lodz, Poland

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Dept. of Medicine I, Div. of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria

  • Centre Hospitalier Universitaire, Montpellier, Montpellier, France

  • Department of Hematology and Oncology, Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milano, Italy

  • Cancer Center Amsterdam, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

  • AbbVie, Inc., North Chicago, IL

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Genentech, Inc., South San Francisico, CA

  • Royal Melbourne Hospital, Peter MacCallum Cancer Centre and University of Melbourne,Melbourne,Australia

Locations

  • Netherlands

  • United States

  • Germany

  • United Kingdom

  • Australia

  • Canada

  • Poland

  • Spain

  • Austria

  • France

  • Italy

Companies

  • Feng Chi Biotech Cor

  • Genentech, Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

  • Rituximab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02005471

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved